Search results for "growth"

showing 10 items of 5134 documents

Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary…

1999

Background —We studied the effects of recombinant growth hormone (rhGH) on exercise capacity and cardiac function in patients with ischemic cardiomyopathy. Methods and Results —Seven patients (aged 55±9 years) with mild to moderate congestive heart failure (ejection fraction 31±4%) who were on standard therapy were included. The patients were studied at baseline, after 3 months of rhGH treatment, and 3 months after rhGH discontinuation. Cardiac function was assessed by exercise capacity, right heart catheterization at rest and after submaximal exercise, MRI, echocardiography, and Holter monitoring. When administered at a dose of 2 IU/d, rhGH doubled the serum concentration of insulin-like …

Cardiac function curveMalemedicine.medical_specialtyCardiac outputCardiomyopathyMyocardial IschemiaHemodynamicsVentricular Function LeftPhysiology (medical)Internal medicinemedicineHumansVentricular remodelingIschemic cardiomyopathyEjection fractionExercise Tolerancebusiness.industryHuman Growth HormoneHemodynamicsMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryHeart failureCardiologyCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Ischemic stroke increases heart vulnerability to ischemia-reperfusion and alters myocardial cardioprotective pathways

2018

Background and Purpose— For years, the relationship between cardiac and neurological ischemic events has been limited to overlapping pathophysiological mechanisms and common risk factors. However, acute stroke may induce dramatic changes in cardiovascular function. The aim of this study was to evaluate how prior cerebrovascular lesions affect myocardial function and signaling in vivo and ex vivo and how they influence cardiac vulnerability to ischemia-reperfusion injury. Methods— Cerebral embolization was performed in adult Wistar male rats through the injection of microspheres into the left or right internal carotid artery. Stroke lesions were evaluated by microsphere counting, tissue sta…

Cardiac function curveMalemedicine.medical_specialtySympathetic nervous systemGrowth Differentiation Factor 15Myocardial ischemiaNitro-oxidative stressHeart VentriclesIschemiaMyocardial Infarction030204 cardiovascular system & hematologyContractility03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIn vivoInternal medicinemedicineAnimalsRats WistarStrokeIschemic StrokeAdvanced and Specialized Nursingbusiness.industryMyocardiumBrainIsolated Heart PreparationHeartmedicine.diseaseRatsStrokeAutonomic nervous systemOxidative Stressmedicine.anatomical_structureEchocardiographyNitrosative StressReperfusion InjuryCardiologyNeurology (clinical)Disease SusceptibilityReceptors Adrenergic beta-1Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryEx vivoAutonomic nervous system Subject terms: Ischemia
researchProduct

miR-133a Enhances the Protective Capacity of Cardiac Progenitors Cells after Myocardial Infarction

2014

Summary miR-133a and miR-1 are known as muscle-specific microRNAs that are involved in cardiac development and pathophysiology. We have shown that both miR-1 and miR-133a are early and progressively upregulated during in vitro cardiac differentiation of adult cardiac progenitor cells (CPCs), but only miR-133a expression was enhanced under in vitro oxidative stress. miR-1 was demonstrated to favor differentiation of CPCs, whereas miR-133a overexpression protected CPCs against cell death, targeting, among others, the proapoptotic genes Bim and Bmf. miR-133a-CPCs clearly improved cardiac function in a rat myocardial infarction model by reducing fibrosis and hypertrophy and increasing vasculari…

Cardiac function curveProgrammed cell deathMyocardial InfarctionGene ExpressionCardiomegalyBiologyBiochemistryArticleMuscle hypertrophyParacrine signallingDownregulation and upregulationmiR-133a; Cardiac Progenitors Cells; Myocardial InfarctionFibrosisREGENERATIONmicroRNAGeneticsmedicineMyocyteAnimalsRNA MessengerOXIDATIVE STRESSlcsh:QH301-705.5ENGINEERED HEART-TISSUElcsh:R5-920Gene Expression ProfilingMICRORNAComputational BiologyCell BiologyMUSCLEmedicine.disease3. Good healthCell biologyRatsAPOPTOSISHYPERTROPHYMicroRNAsDIFFERENTIATIONlcsh:Biology (General)ImmunologyGROWTHRNA Interferencelcsh:Medicine (General)EMBRYONIC STEM-CELLSMyoblasts CardiacDevelopmental BiologyStem Cell Reports
researchProduct

Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone t…

2007

Background and aims Cardiomyocyte apoptosis (CA) is a common feature of end-stage heart failure. We examined whether CA is associated with cardiac dysfunction and remodelling in heart failure due to dilated cardiomyopathy and studied the effect of human growth hormone (hGH) on CA. Methods and results We studied 38 patients, included in a phase III multi-center, randomised, double-blind and placebo-controlled trial of biosynthetic hGH treatment in dilated cardiomyopathy, at baseline and after 14 weeks treatment. Twenty-six patients received hGH and 12 received placebo. CA was quantified in endomyocardial biopsies using the TUNEL assay. CA correlated with left ventricular size (r=0.43, p=0.00…

Cardiomyopathy DilatedMalemedicine.medical_specialtyHeart VentriclesApoptosisPlaceboVentricular Dysfunction LeftInterquartile rangeSomatomedinsInternal medicinemedicineHumansMyocytes CardiacTUNEL assayEjection fractionbusiness.industryHuman Growth HormoneDilated cardiomyopathyStroke VolumeMiddle Agedmedicine.diseaseFas receptorImmunohistochemistryGrowth hormone treatmentEndocrinologyHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuropean journal of heart failure
researchProduct

Differential responses to docosahexaenoic acid in primary and immortalized cardiac cells

2013

Abstract The importance of dietary polyunsaturated fatty acids (PUFAs) in the reduction of cardiovascular disease has been recognized for many years. Docosahexaenoic acid (22:6n3, DHA) is an n-3 PUFA known to affect numerous biological functions and provide cardioprotection; however, the exact molecular and cellular protective mechanism(s) remain unknown. In contrast, DHA also possesses many anti-tumorgenic properties including suppressing cell growth and inducing apoptosis. In the present study, we investigated the effect of DHA toward H9c2 cells (an immortalized cardiac cell line) and neonatal primary cardiomyocytes (NCM). Cells were treated with 0 μM, 10 μM or 100 μM DHA for upto 48 h. C…

CardioprotectionDocosahexaenoic AcidsbiologyCaspase 3Cell SurvivalInterleukin-6Cell growthCytochrome cBlotting WesternCytochromes cGeneral MedicineMitochondrionToxicologyMitochondria HeartCell LineRatsCell biologyDocosahexaenoic acidApoptosiscardiovascular systembiology.proteinAnimalsMyocytes CardiacViability assayCaspaseToxicology Letters
researchProduct

Cardioprotection by gene therapy

2015

Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic-reperfusion injury (IRI). Mimicking endogenous cardioprotection by modulating genes involved in cardioprotective signal transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one or a few genes associated with IRI and cardioprote…

Cardioprotectionmedicine.medical_specialtybiologybusiness.industryGene targetingSphingosine kinase 1Heat shock proteinInternal medicineGene expressionmedicinebiology.proteinCardiologyHepatocyte growth factorSignal transductionCardiology and Cardiovascular MedicinebusinessTranscription factormedicine.drugInternational Journal of Cardiology
researchProduct

From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview

2019

Significance: Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX is associated…

Cardiovascular toxicityPhysiologymedicine.medical_treatmentAntineoplastic drugClinical BiochemistryAntineoplastic Agents030204 cardiovascular system & hematologyPharmacologyBiochemistryCardiac cellcancer immunotherapy; chemotherapy; ErbB2 inhibitors; oxidative/nitrosative stress; tyrosine kinase inhibitors; vascular endothelial growth factor; Antineoplastic Agents; Cardiotoxicity; Humans; Mitochondria; Oxidation-Reduction03 medical and health scienceschemistry.chemical_compoundErbB2 inhibitors cancer immunotherapy chemotherapy oxidative/nitrosative stress tyrosine kinase inhibitors vascular endothelial growth factor0302 clinical medicinetyrosine kinase inhibitorcancer immunotherapy; chemotherapy; ErbB2 inhibitors; oxidative/nitrosative stress; tyrosine kinase inhibitors; vascular endothelial growth factorChemotherapy; ErbB2 inhibitors; vascular endothelial growth factor; tyrosine kinase inhibitors; oxidative/nitrosative stress; cancer immunotherapyCancer immunotherapytyrosine kinase inhibitorsmedicineHumansChemotherapyMolecular BiologyGeneral Environmental ScienceCardioprotectionComprehensive Invited ReviewsChemotherapyErbB2 inhibitorcancer immunotherapyvascular endothelial growth factorbusiness.industryCell BiologyCardiotoxicityMitochondriaVascular endothelial growth factoroxidative/nitrosative streErbB2 inhibitorschemistry030220 oncology & carcinogenesisGeneral Earth and Planetary SciencesbusinessOxidation-ReductionAfter treatmentoxidative/nitrosative stress
researchProduct

Looking for Feminist Pragmatist Roots of Degrowth Ideas: Jane Addams, Charlotte Perkins Gilman, Caroline Bartlett Crane

2022

The aim of the paper is a search of feminist pragmatist roots of degrowth ideas. The starting point is the question of whether in views of the members of the Progressive Movement the idea of progress has always implied the economic (and industrial) growth. Searching for counter-examples leads me to ideas of ecofeminism and feminist critics of capitalism in the previous turn of the centuries. The ideas of ecofeminism were developed by women associated with the Department of Sociology at the University of Chicago and the social settlement Hull House. They observed a link between the exploitation of subordinate members of a society and the degradation of nature in Western cultural values. The …

Caroline Bartlett CraneDegrowthCharlotte Perkins GilmanEco-feminismEnvironmental valuesJane AddamsSocial justiceFeminismPragmatismAnti-consumerism
researchProduct

Haem oxygenase-1 regulates catabolic and anabolic processes in osteoarthritic chondrocytes

2007

Pro-inflammatory cytokines, matrix metalloproteinases (MMPs) and other catabolic factors participate in the pathogenesis of cartilage damage in osteoarthritis (OA). Pro-inflammatory cytokines such as interleukin-1β (IL-1β) mediate cartilage degradation and might be involved in the progression of OA. Previously, we found that haem oxygenase-1 (HO-1) is down-regulated by pro-inflammatory cytokines and up-regulated by IL-10 in OA chondrocytes. The aim of this study was to determine whether HO-1 can modify the catabolic effects of IL-1β in OA cartilage and chondrocytes. Up-regulation of HO-1 by cobalt protoporphyrin IX significantly reduced glycosaminoglycan degradation elicited by IL-1β in OA …

Cartilage ArticularMaleMAP Kinase Signaling Systemmedicine.medical_treatmentInterleukin-1betaProtoporphyrinsMatrix metalloproteinaseChondrocytePathology and Forensic MedicineExtracellular matrixChondrocytesmedicineExtracellularHumansInsulin-Like Growth Factor ICollagen Type IICells CulturedAggrecanAgedbiologyChemistryCartilageGrowth factorOsteoarthritis KneeMatrix MetalloproteinasesCell biologymedicine.anatomical_structureProteoglycanImmunologybiology.proteinFemaleProteoglycansHeme Oxygenase-1The Journal of Pathology
researchProduct

Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment

2014

Background We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients. Methodology/principal findings One-month-old MPS VI rats were given once weekly s.c. injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammato…

Cartilage ArticularMaleMucopolysaccharidosisMucopolysaccharidosis type VIlcsh:MedicineAdministration OralOsteoarthritisOral administrationMedicine and Health SciencesFemurGrowth Platelcsh:Sciencehealth care economics and organizationsGlycosaminoglycansPentosan Sulfuric PolyesterMucopolysaccharidosis VIMultidisciplinaryMucopolysaccharidosis VIPentosan polysulfateBiomechanical Phenomena3. Good healthFemaleAnatomyResearch Articlemedicine.drugmedicine.medical_specialtyInflammatory DiseasesInjections SubcutaneousMovementeducationUrologyBiological AvailabilityResearch and Analysis MethodsDrug Administration ScheduleAutosomal Recessive DiseasesGeneticsmedicineAnimalsAnimal Models of DiseaseBoneAdverse effectMolecular BiologyClinical GeneticsDose-Response Relationship Drugbusiness.industrylcsh:RTherapeutic effectBiology and Life SciencesMucopolysaccharidosesmedicine.diseaseSpineRatsSurgeryAnimal Studieslcsh:QVeterinary ScienceTomography X-Ray ComputedbusinessPLoS ONE
researchProduct